News
Subscribe to our newsletter and never miss the lastest updates.
_edited.jpg)
EraCal closed oversubscribed seed round
16. October 2019
EraCal joins forces with Bernina BioInvest, Redalpine, Life Sciences Fund and private investors to bring first-in-class medicines to patients. We are very grateful for their support of EraCal’s innovative research strategy! This seed investment enables the preclinical development of Era-107, our lead appetite suppressor with remarkable in vivo potency and selectivity, and a platform expansion to new indications.
EraCal wins MIT life science angels award
28. August 2019
EraCal won the MIT life science angels award and enjoyed thrilling days in Boston. Thank you for recognizing our creative science strategy and our global mission!
EraCal received first investment
1. June 2019
The Life Sciences Fund (50% Novartis Venture Fund, 50% UZH Foundation) kicks of EraCal’s lead optimization program. Thank you for joining us on this important mission!
EraCal moves to Schlieren
1. April 2019
EraCal moves to the IncubatorLab at Wagisstrasse 12 in Schlieren, Zurich, one of the best European biotechnology research hubs.
EraCal wins venturekick
31. January 2019
The venturekick jury selected EraCal Therapeutics Ltd. as a top Swiss start-up. Thank you very much for your continuing support of our vision!
EraCal in the scientific news
31. October 2018
Articles in Science Advance and the news of the University of Zurich (English Deutsch) describe part of our drug discovery strategy and its power for translational research.
